New tetanus vaccine enters first human safety tests
NCT ID NCT07598890
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new tetanus vaccine in 80 adults aged 18 and older. The study is randomized and double-blind, meaning neither participants nor doctors know who gets the new vaccine versus an existing one. The main goal is to check for side effects within the first week and month after vaccination, and to see how the immune system responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tetanus vaccine
What this could lead to
If successful, this could lead to a new, safe tetanus vaccine option for adults.
What could go wrong
This is a very early Phase 1 trial with only 80 people, so it's mainly checking safety, not yet proving the vaccine works. Many early-stage vaccines do not advance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TETANUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hubei Provincial Center for Disease Control and Prevention
Wuhan, Hubei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••